Events
-
2024/06/03 Correctseq
CorrectSequence Therapeutics to Participate in BIO International Convention 2024
May 29, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2024/04/13 Correctseq
April 12, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, anno
-
2024/04/02 Correctseq
CorrectSequence Therapeutics’ (Correctseq’s) base editing drug "CS-101 Injection" targeting transfusion-dependent β-thalassemia has obtained IND approval from the National Medical Products Administration (NMPA) of China on April 2, 2024 (acceptance number: CXSL2400021). This is the Chinese first base editing therapy with β-thalassemia. Correctseq is initiating the Phase 1 clinical study for CS-101 (clincialtrials.gov reference # NCT06291961).
-
2024/01/16 Correctseq
January 17-19, 2024, PST, the 5th International Conference on Base Editing, Prime Editing & Related Enzymes will be held at San Diego, California. Dr. Jia Chen, Professor of ShanghaiTech University, Co-founder of CorrectSequence Therapeutics will participate in this conference and give an oral presentation titled” Therapeutic base editing for β-thalassemia” on Jan. 17, at 5:05 - 5:20 pm, PST.
-
2024/01/08 Crectseq
The World’s First Clinical Base Editing Therapy for Hemoglobinopathy
On January 8, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE) technology to help people with severe diseases, announced positive results of its base editing therapy for transfusion-dependent β-thalassemia, CS-101. As a collaboration with the First Affiliated Hospital of Guangxi Medical University, the Investigator-Initiated Trial (IIT) of CS-101 has successfully cured the first treated patient with transfusion-dependent β-thalassemia, resulting in sustained transfusion-free for more than two months.
-
2023/11/24 Correctseq
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that the company and the research teams from ShanghaiTech University, Wuhan University, Fudan University and Children's Hospital of Fudan University published an article entitled “Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs” in Cell Stem Cell on November 20th, 2023, reporting a novel base editing strategy for treating β-hemoglobinopathies with transformer base editor (tBE).
-
2023/10/17 Correctseq
CorrectSequence Therapeutics to Participate in the 18th ASCAT Conference
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that Dr. Susan Mou, CEO of Correctseq and Dr. Lijie Wang, head of Gene Editing Platform of Correctseq, will attend the 18th Academy for Sickle Cell and Thalassaemia Conference (ASCAT) at the County Hall London, UK on October 25-28, 2023. Dr. Lijie Wang, will give an oral presentation on Oct. 28, at 9:00 am - 11:15 am, local time.
-
2023/10/12 Correctseq
Nature Reviews Molecular Cell Biology：Base editing of organellar DNA with programmable deaminases
Recently, Prof. Jia Chen from ShanghaiTech University and Prof. Jin-Soo Kim from National University of Singapore published a review entitled Base editing of organellar DNA with programmable deaminases in Nature Reviews Molecular Cell Biology.